What is it about?
We explain the importance of changing from a world of clinician qualitative interpretation of what is seen, to providing a quantitative measurement of changes in tissue determined by differences in metabolism and regional blood flow. Only by quantitatively calibrating nuclear cameras, then enhancing these differences in tissue and subsequently measuring these differences, is it possible to determine where a person is on a "Health-Spectrum" continuum. Consequently, changes in tissue, prior to the complete transformation to "cancer" can be measured, providing for earlier detection and alternative treatment options. Serial studies provide accurate determination of how rapidly these changes are occurring. By using serial comparisons, clinicians can tell if treatment is working. As a result, treatments can be tailored to the specific response of the patient. This process is accomplished using FMTVDM, patent #9566037.
Featured Image
Why is it important?
This changes the way in which cancer, in this instance breast cancer, is diagnosed and treated.
Perspectives
One of the biggest fears patients have is whether they have cancer. Women worried about breast cancer, due to a lump, abnormal mammogram, family history or genetic markers have been left without absolute answers, absent surgical resection. Qualitative and screening tests often exacerbate that uncertainty. Quantitative FMTVDM addresses that uncertainty for these women and men, their families and doctors.
Richard M Fleming
Read the Original
This page is a summary of: Letter to the Editor: A response to Hruska’s case study on molecular breast imaging and the need for true tissue quantification, January 2019, Springer Science + Business Media,
DOI: 10.1186/s13058-019-1103-6.
You can read the full text:
Contributors
The following have contributed to this page
